Avinger Inc (OQ:AVGR)

Sep 11, 2020 08:30 am ET
Avinger Receives FDA Clearance of Ocelaris Next Generation Image-guided CTO Crossing System
Innovative New Product to be Marketed under TIGEREYE™ Brand Name
Sep 01, 2020 01:05 pm ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment
REDWOOD CITY, CA / ACCESSWIRE / September 1, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriter of its previously announced underwritten public offering has exercised, in full, their option to purchase an additional 1,000,000 shares of the Company's common stock at a price of $0.47 per share. Total gross proceeds to the Company from the offering, includi
Aug 31, 2020 10:50 am ET
Aegis Capital Corp. acted as Sole Bookrunner on a $5.2 Million Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)
NEW YORK, NY / ACCESSWIRE / August 31, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5.2 Million Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Aug 25, 2020 12:00 pm ET
Avinger Closes $5.2 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 25, 2020 / Avinger, Inc. (NASAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 11,063,830 shares of its common stock at a price of $0.47 per share, for total gross proceeds of approximately $5.2 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally,
Aug 20, 2020 08:45 pm ET
Avinger Prices $5.2 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 20, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $5.2 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
Aug 11, 2020 10:05 am ET
Avinger Announces Exercise and Closing of Underwriter’s Over-Allotment
REDWOOD CITY, CA / ACCESSWIRE / August 11, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 2,368,421 shares of the Company's common stock at a price of $0.38 per share. Total gross proceeds to the Company from the Offering, includi
Aug 10, 2020 12:20 pm ET
Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
NEW YORK, NY / ACCESSWIRE / August 10, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $6,000,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Aug 06, 2020 12:30 pm ET
Avinger Closes $6 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 6, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 15,789,474 shares of its common stock at a price of $0.38 per share, for total gross proceeds of approximately $6 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, t
Aug 03, 2020 08:05 pm ET
Avinger Prices $6 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / August 3, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $6 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
Jul 30, 2020 04:01 pm ET
Avinger Reports Second Quarter 2020 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / July 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the second quarter ended June 30, 2020.
Jul 27, 2020 08:30 am ET
Avinger to Announce Second Quarter 2020 Results on July 30, 2020
REDWOOD, CA / ACCESSWIRE / July 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the second quarter 2020 after the close of trading on Thursday, July 30, 2020. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Jul 09, 2020 11:50 am ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
REDWOOD CITY, CA / ACCESSWIRE / July 9, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease ("PAD"), today announced that the underwriters of its previously announced underwritten public offering have exercised, in full, their option to purchase an additional 3,000,000 shares of its common stock at a price of $0.27 per share. Total gross proceeds to the Company from the Offering, including the funds rece
Jun 29, 2020 12:15 pm ET
Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ: AVGR)
NEW YORK, NY / ACCESSWIRE / June 29, 2020 / Aegis Capital Corp. acted as Sole Bookrunner on a $5,400,000 Follow-On Offering for Avinger Inc. (NASDAQ:AVGR)
Jun 26, 2020 02:20 pm ET
Avinger Closes $5.4 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / June 26, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $0.27 per share, for total gross proceeds of approximately $5.4 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Com
Jun 23, 2020 08:40 pm ET
Avinger Prices $5.4 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / June 23, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be $5.4 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.
May 20, 2020 08:30 am ET
Avinger Announces 510(k) Filing of Ocelaris Next Generation Image-guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / May 20, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the Company has submitted a 510(k) application to the U.S. Food & Drug Administration (FDA) for pre-marketing clearance of Ocelaris, a next generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform.
May 13, 2020 04:01 pm ET
May 07, 2020 09:00 am ET
Avinger to Announce First Quarter 2020 Results on May 13, 2020
REDWOOD CITY, CA / ACCESSWIRE / May 7, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2020 after the close of trading on Wednesday, May 13, 2020. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
May 06, 2020 12:00 pm ET
Avinger Announces Exercise and Closing of Underwriter's Over-Allotment Offering
REDWOOD CITY, CA / ACCESSWIRE / May 6, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the underwriters of its previously announced underwritten public offering have exercised in full their option to purchase an additional 1,890,000 shares of its common stock at a price of $0.25 per share. Total gross proceeds to the Company from the Offering, including the funds received from the p
Apr 30, 2020 11:17 am ET
Avinger Closes $3.15 Million Equity Offering
REDWOOD CITY, CA / ACCESSWIRE / April 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the closing of an underwritten public offering of 12,600,000 shares of its common stock at a price of $0.25 per share, for total gross proceeds of approximately $3.15 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the C
Apr 27, 2020 09:25 pm ET
Avinger Prices $3.15 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / April 27, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $3.15 million before deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company. The proposed offering equates to 12.6 million shares of t
Apr 15, 2020 09:00 am ET
Avinger Reports Preliminary First Quarter 2020 Revenue Results
Provides Update on COVID-19 Impact and Response
Mar 05, 2020 04:05 pm ET
Avinger Reports Fourth Quarter 2019 Financial Results
REDWOOD CITY, CA / ACCESSWIRE / March 5, 2020 / Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported results for the fourth quarter and full year ended December 31, 2019.
Feb 27, 2020 08:00 am ET
Avinger to Announce Fourth Quarter 2019 Financial Results on March 5, 2020
REDWOOD CITY, CA / ACCESSWIRE / February 27, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the fourth quarter 2019 after the close of trading on Thursday, March 5, 2020. The Company will host a conference call beginning at 1:30 pm PT/4:30 pm ET.
Feb 25, 2020 08:30 am ET
Avinger Announces Publication of SCAN Clinical Study in Peer-Reviewed Journal
OCT Imaging with Pantheris Superior or Equivalent to IVUS on all Parameters
Feb 04, 2020 08:00 am ET
Avinger's Pantheris Featured in Live Case Transmission at LINC 2020
REDWOOD, CA / ACCESSWIRE / February 4, 2020 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), announced today that its Pantheris atherectomy system was featured in a live case transmission at the Leipzig Interventional Course (LINC) 2020, a leading global forum for new methods in the field of vascular medicine held from January 28 through January 31 in Leipzig, Germany. In addition to performing the live case, Dr. Arne Sch
Jan 31, 2020 04:01 pm ET
Avinger Closes $4.5 Million Equity Offering
REDWOOD CITY, CA / ACCESSWIRE / January 31, 2020 / Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 6,428,572 shares of its common stock at a price of $0.70 per share, for total gross proceeds of approximately $4.5 million, before deducting underwriting discounts, commissions and other offering expenses payable by the Company. Additionally, the Company has granted the underwriters a 45-day option to purchase up to 15% additional shares of common stock to cover o
Jan 30, 2020 08:30 am ET
Avinger Announces the Passing of Director Donald A. Lucas
REDWOOD CITY, CA / ACCESSWIRE / January 30, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the death of Donald A. Lucas, independent director and chairman of the audit committee, on Tuesday, January 28, 2020.
Jan 28, 2020 08:05 pm ET
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
REDWOOD CITY, CA / ACCESSWIRE / January 28, 2020 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5 million before deducting underwriting discounts and commissions and other estimated offering expenses. The proposed offering equates to 6,428,572 shares of the Company's common stock at a price of $0.70 per share. The Company intends to use the net proceeds from this offering to fund wor
Jan 23, 2020 08:00 am ET
Avinger Enrolls First Patient in IMAGE-BTK Clinical Study Evaluating Safety and Efficacy Endpoints for Pantheris SV
Post-Market Study Intended to Support Commercial Expansion of Small Vessel Image-Guided Atherectomy Device
Jan 09, 2020 08:30 am ET
Avinger Announces Successful First Procedures in Europe with Ocelaris Chronic Total Occlusion (CTO) Image-Guided Crossing Device
REDWOOD CITY, CA / ACCESSWIRE / January 9, 2020 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the first clinical experiences with the Ocelaris next-generation CTO crossing system utilizing Avinger's proprietary image-guided technology platform.
Dec 17, 2019 08:30 am ET
Avinger Receives CE Marking for Ocelaris, a Next-Generation Image-Guided CTO Crossing System
REDWOOD CITY, CA / ACCESSWIRE / December 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based systems for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has gained Conformité Européenne (CE) Marking for Ocelaris, a next-generation chronic total occlusion (CTO) crossing system utilizing Avinger's proprietary image-guided technology platform. CE Marking allows clinical use of Ocelaris in the European Union (EU) and certain other countries t
Dec 16, 2019 08:30 am ET
Avinger Appoints Healthcare Veteran Tamara Elias, MD, to Board of Directors
REDWOOD, CA / ACCESSWIRE / December 16, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), is pleased to announce that Tamara Elias, MD, has been appointed to the Company's Board of Directors, effective December 12, 2019. Dr. Elias has been actively involved with healthcare for more than 20 years in strategic consulting, private equity
Nov 05, 2019 04:01 pm ET
Avinger Reports Third Quarter 2019 Financial Results
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Oct 29, 2019 09:00 am ET
Avinger to Announce Third Quarter 2019 Financial Results on November 5, 2019
REDWOOD CITY, CA / ACCESSWIRE / October 29, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the third quarter 2019 after the close of trading on Tuesday, November 5, 2019. The Company will host a conference call beginning at 4:30pm ET.
Oct 09, 2019 08:00 am ET
Avinger Expands US Reach with Seven New Accounts in Third Quarter
Includes New Sites in Florida, Georgia and Arizona PAD Markets
Sep 18, 2019 08:00 am ET
Sep 17, 2019 08:00 am ET
Avinger to Present at Ladenburg Thalmann Healthcare Conference on September 24
REDWOOD CITY, CA / ACCESSWIRE / September 17, 2019 / Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Ladenburg Thalmann Healthcare Conference on Tuesday, September 24, 2019, at 2:00 pm Eastern Time, at the Sofitel Hotel in New York City. The presentation will be webcast, both live and in an archived format, with a link available at www.avinger.com under “Investors,” then “Events &a
Sep 10, 2019 08:00 am ET
Avinger Announces Commercial Launch and First Patients Treated in Hong Kong
REDWOOD CITY, CA / ACCESSWIRE / September 10, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced the commercial launch of its Lumivascular products in Hong Kong. Avinger has an exclusive distribution agreement with Integmed Ltd. for the sale and marketing of Avinger’s Pantheris image-guided atherectomy and Ocelot image-guided chronic total occlusion (CTO
Sep 04, 2019 08:30 am ET
Avinger Supports Peripheral Artery Disease (PAD) Awareness Month with Physician and Patient Programs in September
REDWOOD CITY, CA / ACCESSWIRE / September 4, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), urges greater awareness for this disease state in support of PAD Awareness Month in September. Avinger plans to support PAD Awareness Month through the distribution of informational articles and content related to PAD throughout September, directed both at physicians and patients.
Aug 29, 2019 08:00 am ET
Avinger Announces 50th Patient Treated in Pantheris SV Initial Launch
Preparing for Full Commercial Launch in September
Aug 26, 2019 04:02 pm ET
Avinger Closes $4.5 Million Equity Offering
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD) today announced the closing of an underwritten public offering of 3,813,559 shares of its common stock at a price of $1.18 per share, for...
Aug 21, 2019 09:00 pm ET
Avinger Prices $4.5 Million Underwritten Public Offering of Common Stock
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced the pricing of an underwritten public offering with gross proceeds to the Company expected to be approximately $4.5...
Aug 21, 2019 04:15 pm ET
Avinger Announces Proposed Underwritten Public Offering of Common Stock
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that it intends to offer shares of its common stock for sale in an underwritten public offering. In addition, the...
Aug 19, 2019 07:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at AMP 2019 Clinical Conference
REDWOOD, CA / ACCESSWIRE / August 19, 2019 / Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for the diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the Company’s Lumivasc
Jul 31, 2019 04:01 pm ET
Avinger Reports 26% Sequential Revenue Growth in Second Quarter 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Jul 29, 2019 08:00 am ET
Avinger Announces Pantheris SV Limited Launch and Successful Treatment of First Patients in the United States
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that physicians...
Jul 26, 2019 09:00 am ET
Avinger to Announce Second Quarter 2019 Financial Results on July 31, 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced...
Jul 16, 2019 08:00 am ET
Avinger Announces Presentations by Key Opinion Leaders at CVC 2019
REDWOOD CITY, CA / ACCESSWIRE / July 16, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced five podium presentations and a live case featuring the Company’s Lumivascular technology at the a
Jul 10, 2019 09:40 am ET
Avinger Enrolls First 50 Patients in INSIGHT Clinical Trial
Positive early outcomes in complex in-stent restenosis cases with few therapeutic options
Jul 08, 2019 07:30 am ET
Avinger Announces Commercial Launch of Ocelot in Australia
First Patients Treated Successfully in Australia with Image-Guided CTO-Crossing Device
Jun 21, 2019 04:05 pm ET
Avinger to Effect One-for-Ten Reverse Stock Split
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced that the Company will effect a...
Jun 04, 2019 07:00 am ET
Avinger Announces Distribution Agreement for Hong Kong
REDWOOD CITY, CA / ACCESSWIRE / June 4, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first-ever image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced it has entered into an exclusive distribution agreement with Integmed Ltd. for the sales and marketing of Avinger's Lumivascular products in Hong Kong. Initial product shipments are anticipated during the current quarter and first patient treatments in Hong Kong are expected to commence in the third quarter of 2019.
May 30, 2019 04:00 pm ET
Avinger Announces Presentations by Key Opinion Leaders at New Cardiovascular Horizons Annual Conference
REDWOOD CITY, CA / ACCESSWIRE / May 30, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of Peripheral Artery Disease (PAD), today announced four podium presentations featuring the company's Lumivascular technology at the New Cardiovascular Horizons (NCVH) annual conference, which is taking place this week in New Orleans.
May 08, 2019 04:01 pm ET
Avinger Provides First Quarter 2019 Shareholder Update
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
May 02, 2019 12:25 pm ET
Avinger to Announce First Quarter 2019 Financial Results on May 8, 2019
REDWOOD CITY, CA / ACCESSWIRE / May 2, 2019 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that it will release its financial results for the first quarter 2019 after the close of trading on Wednesday, May 8, 2019. The Company will host a conference call beginning at 1:30pm PT/4:30pm ET.
Apr 18, 2019 07:55 am ET
Market Trends Toward New Normal in GrafTech International, Avinger, OraSure Technologies, Adamis Pharmaceuticals, Crinetics Pharmaceuticals, and Wayside Technology Group — Emerging Consolidated Expect
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of GrafTech International Ltd. (NYSE:EAF), Avinger, Inc. (NASDAQ:AVGR),...
Apr 17, 2019 08:00 am ET
Avinger Announces Issuance of New U.S. Patent and Receives Notice of Allowance for Five Additional U.S. Patents
Extensive Intellectual Property Portfolio Now Includes 149 Patents and Applications
Apr 15, 2019 08:00 am ET
Apr 10, 2019 08:00 am ET
Avinger Receives FDA Clearance of Pantheris SV Device
Avinger, Inc. (Nasdaq: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced that the Company received 510(k) clearance from the U.S....
Mar 27, 2019 08:00 am ET
Avinger Receives $6.2 Million from Warrant Exercises
REDWOOD CITY, CA / ACCESSWIRE / March 27, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of image-guided, catheter-based systems for the diagnosis and treatment of patients with Peripheral Artery Disease (PAD), announced today that it has received $6.2 million in net proceeds from holders exercising common stock purchase warrants at an exercise price of $0.40 per share. The warrants were issued as part of the units sold in the Company's public offering which closed on November 1, 2018. The proceeds from the warrant offering wou
Mar 06, 2019 04:05 pm ET
Avinger Provides Fourth Quarter and Full Year 2018 Shareholder Update
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today reported...
Mar 01, 2019 08:30 am ET
Avinger to Present at Oppenheimer Healthcare Conference on March 20
REDWOOD CITY, CA / ACCESSWIRE / March 1, 2019 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced today announced that Jeff Soinski, CEO, will present at the Oppenheimer & Co. 29th Annual Healthcare Conference on Wednesday, March 20, 2019, at 1:00 pm Eastern Time, at the Westin New York Grand Central in New York City.
Feb 28, 2019 08:30 am ET
Avinger to Announce Fourth Quarter and Full Year 2018 Financial Results on March 6, 2019
Avinger, Inc. (Nasdaq: AVGR), a commercial-stage medical device company marketing the first and only intravascular image-guided, catheter-based system for diagnosis and treatment of patients with Peripheral Artery Disease (PAD), today announced...
Jan 28, 2019 08:00 am ET
Avinger’s Pantheris SV (Small Vessel) Featured in Live Case Transmission at Leipzig Interventional Course (LINC) 2019
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Pantheris® SV (Small Vessel) image-guided atherectomy system was featured in a live case transmission at...
Dec 19, 2018 06:00 am ET
Avinger Announces Preliminary Analysis of Results from SCAN Clinical Study
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the release of the preliminary analysis of results from its SCAN clinical study, a post-market study comparing optical...
Dec 13, 2018 07:00 am ET
Avinger Announces Successful Treatment of 500th Patient with Next-Generation Pantheris Device
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 59 sites globally have successfully treated more than 500 patients with the next-generation Pantheris...
Dec 06, 2018 08:00 am ET
Avinger Announces Commercial Launch in Australia
Avinger, Inc. (NASDAQ:AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the...
Nov 21, 2018 08:50 am ET
Market Trends Toward New Normal in Wilhelmina International, Eyenovia, aTyr Pharma, Avinger, Viacom, and Axsome Therapeutics — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Wilhelmina International, Inc. (NASDAQ:WHLM), Eyenovia, Inc....
Nov 15, 2018 09:55 am ET
Avinger Announces Successful Treatment of First Patients Globally with Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
REDWOOD CITY, CA / ACCESSWIRE / November 15, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the successful treatment of the first nine patients with Pantheris SV (Small Vessel) at two separate hospitals in Germany.
Nov 13, 2018 04:01 pm ET
Avinger Provides Third Quarter 2018 Shareholder Update
REDWOOD CITY, CA / ACCESSWIRE / November 13, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today reported results for the third quarter ended September 30, 2018.
Nov 07, 2018 08:45 am ET
Avinger to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018
REDWOOD CITY, CA / ACCESSWIRE / November 7, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced its participation at the Canaccord Genuity Medical Technologies & Diagnostics Forum 2018. The conference is being held on Thursday, November 15, 2018 at the Westin Grand Central Hotel in New York City.
Nov 05, 2018 07:30 am ET
Avinger to Announce Third Quarter 2018 Financial Results on November 13, 2018
REDWOOD CITY, CA / ACCESSWIRE / November 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter 2018 after the close of trading on Tuesday, November 13, 2018. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET.
Oct 30, 2018 08:30 am ET
Avinger Announces Pricing of $10 Million Underwritten Public Offering
REDWOOD CITY, CA / ACCESSWIRE / October 30, 2018 / Avinger, Inc. (NASDAQ: AVGR), a commercial-stage medical device company that designs and develops the first-ever image-guided, catheter-based system that diagnoses and treats patients with peripheral artery disease (PAD), today announced the pricing of an underwritten public offering for gross proceeds of approximately $10 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Avinger.
Oct 18, 2018 08:30 am ET
Avinger Receives CE Marking Approval for Pantheris SV, a New Image-Guided Atherectomy Device Designed to Treat Smaller Vessels
REDWOOD CITY, CA / ACCESSWIRE / October 18, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced Conformité Européenne (CE) Marking approval of Pantheris SV (Small Vessel), a product line extension of the Lumivascular atherectomy system. CE Marking allows for distribution of Pantheris SV in the European Union (EU) and certain other countries that recognize the CE Marking. Pantheris SV is not available commercially in the United States at this time.
Sep 05, 2018 08:30 am ET
Avinger Announces Successful Treatment of 200th Patient with Next-Generation Pantheris Device
REDWOOD CITY, CA / ACCESSWIRE / September 5, 2018 / Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that physicians in 35 sites globally have successfully treated over 200 patients with the next-generation Pantheris image-guided atherectomy system for the treatment of peripheral artery disease (PAD).
Aug 30, 2018 08:30 am ET
Avinger Announces 510(k) Filing of Pantheris Small Vessel Device
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company submitted a new 510(k) application to the U.S Food Drug Administration (FDA) for the Pantheris SV (Small...
Aug 29, 2018 08:30 am ET
Avinger Receives New Patent Covering Pantheris Image-Guided Atherectomy System
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the issuance of an important new patent covering the Company’s Pantheris image-guided atherectomy system. The U.S....
Aug 28, 2018 08:30 am ET
Avinger Announces Participation in Upcoming Investor Conferences
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that management of Avinger will present at the following investor conferences: Rodman Renshaw 20th Annual Global...
Aug 23, 2018 08:30 am ET
Avinger Completes Enrollment in SCAN Clinical Study
Avinger, Inc. (NASDAQ: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has completed enrollment in the SCAN clinical study, a post-market study comparing optical coherence tomography...
Aug 13, 2018 04:00 pm ET
Avinger Announces Second Quarter 2018 Financial Results
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2018. Second Quarter and Recent Highlights Revenue of $2.1 million for...
Aug 06, 2018 10:30 am ET
Avinger to Report Second Quarter 2018 Results on Monday, August 13, 2018
Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), will announce its second quarter 2018 results for the period ended June 30, 2018 on Monday, August 13, 2018 after market close. A...
Jul 12, 2018 08:30 am ET
Avinger Announces Pricing of $3.55 Million Registered Direct Offering
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a securities purchase agreement with certain institutional investors providing for the purchase...
Jul 10, 2018 08:30 am ET
Avinger Appoints Jaafer Golzar, MD, FACC, FSCAI, as Chief Medical Officer
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the appointment, effective immediately, of Jaafer Golzar, MD, as the Company’s Chief Medical Officer. Dr. Golzar provides...
Jun 26, 2018 08:30 am ET
Avinger Announces Successful Treatment of First Patients with Next-Generation Pantheris in Several Centers throughout the US
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that several physicians have successfully treated over 40 patients in the US across 13 sites with the next-generation...
Jun 21, 2018 08:30 am ET
Avinger’s Ocelot Technology Featured in Live Case Transmission at Complex Cardiovascular Catheter Therapeutics (C3) 2018
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that its Ocelot image-guided chronic total occlusion (CTO) crossing device was featured in a live case on June 19th at...
Jun 14, 2018 08:30 am ET
Avinger Announces First Patients Enrolled in Post-Market Study Comparing Pantheris OCT Imaging to Intravascular Ultrasound
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the initiation of the SCAN study, a post-market study comparing optical coherence tomography (OCT) with intravascular...
Jun 13, 2018 08:30 am ET
Avinger Appoints Mark Weinswig as Chief Financial Officer
Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that Mark Weinswig will join the Company, and serve in the role of Chief Financial Officer...
May 30, 2018 08:30 am ET
Avinger Announces Presentations and Posters Featuring Lumivascular Technology at New Cardiovascular Horizons Annual Conference
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of sessions and posters highlighting the company’s Lumivascular technology at the New Cardiovascular Horizons...
May 29, 2018 08:30 am ET
Avinger to Present at the 8th Annual LD Micro Invitational
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it will be presenting at the 8th Annual LD Micro Invitational at the Luxe Sunset Boulevard Hotel in Bel Air,...
May 24, 2018 09:31 am ET
Should you buy stock in Apple, Advanced Micro Devices, Avinger, Best Buy Inc. or Williams-Sonoma?
CHICAGO, May 24, 2018 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AAPL, AMD, AVGR, BBY, and WSM....
May 23, 2018 08:30 am ET
Avinger Receives FDA Clearance of Next Generation Pantheris Device
Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company received 510(k) clearance from the U.S. Food Drug Administration (FDA) for its next generation...
May 14, 2018 04:15 pm ET
Avinger Announces First Quarter 2018 Financial Results
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the first quarter ended March 31, 2018.   First Quarter and Recent Highlights Revenue of $1.8 million for...
May 04, 2018 08:00 am ET
Avinger to Announce First Quarter 2018 Financial Results on May 14, 2018
Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter 2018 after the close of trading on Monday, May 14, 2018....
Apr 30, 2018 08:30 am ET
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Charing Cross International Symposium 2018
Charing Cross Symposium (CX) is the longest running vascular and endovascular symposium in Europe and one of the largest in the world
Mar 29, 2018 09:00 am ET
Avinger Announces First-in-Patient use of Extended Nosecone Version of Next Generation Pantheris
Three patients successfully treated using next generation image-guided atherectomy device with enhanced tissue removal capacity for treatment of peripheral artery disease
Mar 21, 2018 08:00 am ET
Avinger Enters into Settlement Agreement for All Outstanding Securities Class Action Litigation
REDWOOD CITY, Calif., March 21, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a binding memorandum of...
Mar 19, 2018 04:01 pm ET
Avinger Announces Fourth Quarter and Full Year 2017 Results
REDWOOD CITY, Calif., March 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the fourth quarter and full year ended...
Mar 13, 2018 08:00 am ET
Avinger Provides Update on U.S. Intellectual Property Portfolio
Three New Patents Allowed or Issued for Proprietary CTO Crossing Devices
Mar 06, 2018 08:00 am ET
Avinger to Announce Fourth Quarter 2017 and Full Year 2017 Results on March 19th, 2018
REDWOOD CITY, Calif., March 06, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the fourth quarter and full...
Mar 05, 2018 08:00 am ET
Avinger Announces Participation in Cowen and Company 38th Annual Health Care Conference
REDWOOD CITY, Calif, March 05, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will be participating in the Cowen and Company 38th Annual...
Mar 02, 2018 08:00 am ET
Avinger Regains Compliance with Nasdaq Listing Requirements
REDWOOD CITY, Calif., March 02, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (Nasdaq:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced it has regained compliance with Nasdaq listing requirements. 
Feb 20, 2018 08:00 am ET
OPS Code Established for Peripheral Vascular OCT Imaging in Germany
New Code is a Potential Precursor to Higher Reimbursement Levels in German DRG System
Feb 16, 2018 01:30 pm ET
Avinger Announces Closing of $18 Million Underwritten Public Offering
Secured Lenders Convert $38 Million of Debt into Equity
Feb 14, 2018 08:30 am ET
Avinger Announces Pricing of $18 Million Underwritten Public Offering
Secured Lenders Convert $38 Million of Debt into Equity
Feb 02, 2018 08:00 am ET
Avinger’s Next Generation Pantheris Featured in Live Case Transmission at Leipzig Interventional Course 2018
Leipzig Interventional Course is a leading global forum for new methods and technology in the field of vascular medicine
Jan 30, 2018 04:45 pm ET
Avinger Announces Reverse Stock Split
REDWOOD CITY, Calif., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company will effect a 1-for-40 reverse stock split of the Company's...
Jan 19, 2018 08:00 am ET
Avinger Granted Continued Listing Decision From Nasdaq
REDWOOD CITY, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has...
Jan 03, 2018 08:30 am ET
Avinger Announces Treatment of First Patients Globally With Next Generation Pantheris
Seven patients successfully treated using next generation image-guided atherectomy device for treatment of peripheral artery disease
Dec 21, 2017 08:30 am ET
Avinger Announces 510(k) Filing of Next Generation Pantheris Device
REDWOOD CITY, Calif., Dec. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration...
Dec 20, 2017 08:30 am ET
Avinger Receives CE Marking Approval for Next Generation Pantheris Image-Guided Atherectomy Device
Features included in next generation device represent an important advance in the Pantheris Lumivascular System used for treatment of peripheral artery disease
Dec 14, 2017 04:01 pm ET
Avinger Secures Waiver and Consent to CRG Loan Agreement
REDWOOD CITY, Calif., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer and manufacturer of image-guided, catheter-based systems for the treatment of peripheral arterial disease (PAD) and pioneer of the Lumivascular approach to treating vascular disease,...
Dec 11, 2017 04:15 pm ET
Avinger Announces Change in Board Leadership
Dr. John B. Simpson Departs Company; James G. Cullen Appointed Non-executive Chairman
Nov 09, 2017 04:01 pm ET
Avinger Announces Third Quarter 2017 Results
REDWOOD CITY, Calif., Nov. 09, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (“Avinger” or the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the third quarter ended September 30, 2017.
Nov 06, 2017 07:30 am ET
Avinger Enters into Common Stock Purchase Agreement for up to $15.0 Million with Lincoln Park Capital
REDWOOD CITY, Calif., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it has entered into a $15 million common stock purchase...
Oct 19, 2017 04:01 pm ET
Avinger Announces First Patient Enrolled in its IDE Study of the Pantheris Image-Guided Atherectomy System for Treatment of In-Stent Restenosis
REDWOOD CITY, Calif., Oct. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced initiation of INSIGHT, a prospective, global, single arm, multi-center study to evaluate the safety and effectiveness of the Pantheris® Lumivascular Atherectomy System for treating in-stent restenosis (ISR) in lower extremity arteries....
Sep 26, 2017 04:01 pm ET
Avinger Receives CE Marking Approval for In-Stent Restenosis Treatment Indication With Pantheris Image-Guided Atherectomy
REDWOOD CITY, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the Pantheris® Lumivascular atherectomy system....
Sep 01, 2017 11:50 pm ET
INVESTOR ALERT: Goldberg Law PC Announces a Securities Class Action Lawsuit against Avinger, Inc.
LOS ANGELES, Sept. 01, 2017 (GLOBE NEWSWIRE) -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR) for violations of §§11, 12(a)(2) and 15 of the Securities Act of 1933....
Aug 24, 2017 05:51 pm ET
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Avinger, Inc. and Reminds Investors with Losses to Contact the Firm
IRVINE, Calif., Aug. 24, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces a securities class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline....
Aug 23, 2017 06:46 pm ET
Lawsuit for Investors in Avinger Inc (NASDAQ:AVGR) announced by Shareholders Foundation
SAN DIEGO, Aug. 23, 2017 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit was filed for certain purchasers of shares of Avinger Inc (NASDAQ:AVGR) over alleged violations of Federal Securities Laws by Avinger Inc in connection with Avinger’s initial public offering (“IPO”)....
Aug 23, 2017 03:46 pm ET
APPROACHING DEADLINE: Lundin Law PC Announces Securities Class Action Lawsuit against Avinger, Inc. and Reminds Investors with Losses to Contact the Firm
LOS ANGELES, Aug. 23, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. ("Avinger" or the "Company") (Nasdaq: AVGR) for possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering ("IPO") on January 30, 2015, should contact the firm prior to the September 5, 2017 lead plaintiff motion deadline....
Aug 22, 2017 08:47 pm ET
EQUITY ALERT: Goldberg Law PC Announces the Filing of a Securities Class Action Lawsuit against Avinger, Inc.
LOS ANGELES, Aug. 22, 2017 /PRNewswire/ -- Goldberg Law PC, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Avinger, Inc. ("Avinger" or the "Company") (Nasdaq: AVGR) for violations of §§11, 12(a)(2) and 15 of the Securities Act of 1933....
Aug 22, 2017 04:00 pm ET
AVGR Investors Deadline Reminder: Hagens Berman Reminds Investors in Avinger, Inc. of the September 5, 2017 Lead Plaintiff Deadline in the Pending Securities Class Action
SAN FRANCISCO, Aug. 22, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP reminds investors in Avinger, Inc. (NASDAQ:AVGR) of the September 5, 2017 Lead Plaintiff deadline in the pending securities class action....
Aug 14, 2017 06:37 pm ET
EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., Aug. 14, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a securities class action lawsuit against Avinger, Inc. ("Avinger" or the "Company") (Nasdaq: AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company's initial public offering on January 30, 2015 (the "IPO"), are encouraged to contact the Firm in advance of the September 5, 2017 lead plaintiff motion deadline....
Aug 11, 2017 11:56 pm ET
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Avinger, Inc. and Reminds Investors with Losses to Contact the Firm
LOS ANGELES, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR) for possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering (“IPO”) on January 30, 2015, should contact the firm prior to the September 5, 2017 lead plaintiff motion deadline....
Aug 01, 2017 11:10 am ET
Scott+Scott, Attorneys at Law, LLP Announces Deadline for Lead Plaintiff Motions in Federal Securities Case Against Avinger, Inc. (AVGR)
NEW YORK, Aug. 1, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, announces that September 5, 2017, is the deadline for interested investors to file motions to be the lead plaintiff in the federal securities action pending against Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR) and certain of its senior officers and directors.  The lawsuit alleges violations of federal securities laws.  If you purchased Avinger shares between January 30, 2015 and July 11, 2016, you are encouraged to contact Scott+S...
Jul 26, 2017 04:01 pm ET
Avinger to Announce Second Quarter 2017 Results on August 8, 2017
REDWOOD CITY, Calif., July 26, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2017 after the close of trading on Tuesday, August 8, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET....
Jul 25, 2017 04:00 pm ET
AVGR Investors Update: Hagens Berman Updates Investors in Avinger, Inc. Concerning Securities Class Action Pending in Federal Court and Reminds Them of the September 5, 2017 Lead Plaintiff Deadline
SAN FRANCISCO, July 25, 2017 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro LLP updates investors in Avinger, Inc. (NASDAQ:AVGR) in the securities class action originally filed in the Superior Court of the State of California for the County of San Mateo and now pending in the United States District Court for the Northern District of California, and reminds them of the September 5, 2017 Lead Plaintiff deadline....
Jul 07, 2017 04:10 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Avinger, Inc. (AVGR) & Lead Plaintiff Deadline: September 5, 2017
NEW YORK, July 7, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR) and certain of its officers, on behalf of shareholders who purchased Avinger common stock pursuant to the Registration Statement and Prospectus issued in connection with Avinger's initial public offering ("IPO") on or around January 30, 2015. Such investors are encouraged to join this case by visiting the firm's site: http://www.bgandg.com/avgr. ...
Jul 07, 2017 09:00 am ET
Bottini & Bottini, Inc. Files Securities Class-Action Lawsuit Against Avinger, Inc.
SAN DIEGO, July 07, 2017 (GLOBE NEWSWIRE) -- Bottini & Bottini, Inc., a law firm specializing in securities litigation, announces that it has filed a class-action lawsuit on behalf of all persons who purchased the common stock of Avinger, Inc. (“Avinger”) (NASDAQ:AVGR) pursuant to the Registration Statement and Prospectus issued in connection with Avinger’s initial public offering (“IPO”). The lawsuit—pending in the United States District Court for the Northern District of California—seeks to recover damages under the federal securities laws for those who purchased or otherwise acquired ...
Jun 20, 2017 05:00 pm ET
AVGR Investors Alert: Hagens Berman Alerts Investors in Avinger, Inc. to Securities Class Action
SAN FRANCISCO, June 20, 2017 /PRNewswire/ -- Hagens Berman Sobol Shapiro LLP alerts investors in Avinger, Inc. (NASDAQ: AVGR) to the securities class action pending in Superior Court of the State of California for the County of San Mateo....
Jun 19, 2017 04:02 pm ET
SHAREHOLDER ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, June 19, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR) for possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering (“IPO”) on January 30, 2015, should contact the firm....
Jun 14, 2017 04:15 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Avinger, Inc. - AVGR
NEW YORK, June 14, 2017 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jun 07, 2017 03:25 pm ET
IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., June 07, 2017 (GLOBE NEWSWIRE) -- Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company’s initial public offering on January 30, 2015 (the “IPO”), are encouraged to contact the Firm....
Jun 06, 2017 02:32 pm ET
IMPORTANT EQUITY ALERT: Lundin Law PC Announces Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, June 6, 2017 /PRNewswire/ -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. ("Avinger" or the "Company") (Nasdaq: AVGR) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering ("IPO") on January 30, 2015, should contact the firm....
Jun 05, 2017 03:25 pm ET
IMPORTANT INVESTOR ALERT: Lundin Law PC Announces a Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
LOS ANGELES, June 05, 2017 (GLOBE NEWSWIRE) -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Avinger, Inc. (“Avinger” or the “Company”) (Nasdaq:AVGR) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired Avinger shares pursuant and/or traceable to its initial public offering (“IPO”) on January 30, 2015, should contact the firm....
Jun 02, 2017 05:42 pm ET
IMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces Securities Class Action Lawsuit against Avinger, Inc. and Encourages Investors with Losses to Contact the Firm
IRVINE, Calif., June 2, 2017 /PRNewswire/ -- Khang & Khang LLP (the "Firm") announces the filing of a class action lawsuit against Avinger, Inc. ("Avinger" or the "Company") (Nasdaq: AVGR). Investors who purchased or otherwise acquired shares pursuant and/or traceable to the Company's initial public offering on January 30, 2015 (the "IPO"), are encouraged to contact the Firm....
May 30, 2017 12:48 pm ET
AVINGER ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Avinger, Inc. To Contact The Firm
NEW YORK, May 30, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR) of the filing of a securities lawsuit against the Company. ...
May 09, 2017 02:30 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Avinger, Inc. (AVGR)
NEW YORK, May 9, 2017 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR). Such investors are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/avgr.  ...
May 08, 2017 05:07 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Avinger, Inc. -- AVGR
NEW YORK, May 8, 2017 /PRNewswire/ -- Levi & Korsinsky, LLP announces it has commenced an investigation of Avinger, Inc. ("Avinger") (NASDAQ: AVGR) concerning possible violations of federal securities laws. ...
May 05, 2017 06:41 pm ET
AVINGER INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Avinger Inc. To Contact The Firm
NEW YORK, May 5, 2017 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Avinger Inc. ("Avinger" or the "Company") (NASDAQ: AVGR)....
May 04, 2017 04:01 pm ET
Avinger Announces First Quarter 2017 Results
REDWOOD CITY, Calif., May 04, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the first quarter ended March 31, 2017....
May 04, 2017 01:39 pm ET
Scott+Scott, Attorneys at Law, LLP Announces Investigation of Avinger, Inc. (AVGR)
NEW YORK, May 4, 2017 /PRNewswire/ -- Scott+Scott, Attorneys at Law, LLP ("Scott+Scott"), a national shareholder and consumer rights litigation firm, announces an investigation into Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR) and certain of its senior officers and directors, for violating federal securities laws.  If you purchased Avinger stock pursuant or traceable to the Company's initial public offering ("IPO") on or about January 30, 2015, you are encouraged to contact Scott+Scott at (844) 818-6982 for more information....
Apr 24, 2017 04:01 pm ET
Avinger’s Pantheris Named a 2017 Gold Edison Award Winner
REDWOOD CITY, Calif. and NEW YORK, April 24, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), was honored at the 2017 Edison Awards™ in the Medical/Dental Surgical Tool category with gold for Pantheris, the first-ever image-guided atherectomy device for the treatment of PAD. Avinger was nominated among hundreds of the world’s most recognized companies to acknowledge dedication and commitment of innovation to create a positive impact in the world....
Apr 10, 2017 04:01 pm ET
Avinger Provides Strategic Update
REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today provided an update on several aspects of its business, including preliminary results for the first quarter of 2017, an organizational realignment, and continued progress on product development and clinical initiatives.  The Company also announced that it has been conducting a review of various strategic alternatives focused on maximizing shareholder value. Potential strategic alternatives being explored...
Feb 22, 2017 04:01 pm ET
Avinger to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that the Company will be participating in two upcoming investor conferences....
Feb 21, 2017 04:01 pm ET
Avinger to Announce Fourth Quarter and Full Year 2016 Results on March 6, 2017
REDWOOD CITY, Calif., Feb. 21, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it will release its financial results for the fourth quarter and full year 2016 after the close of trading on Monday, March 6, 2017. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET....
Jan 25, 2017 04:01 pm ET
Avinger Announces 24-Month Outcomes from the Pivotal VISION Study of Lumivascular Technology for Peripheral Artery Disease
REDWOOD CITY, Calif. and LEIPZIG, Germany, Jan. 25, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced positive two-year clinical data from the pivotal VISION study of the company’s Lumivascular™ technology....
Jan 19, 2017 04:01 pm ET
Avinger Announces Presentations Showcasing Lumivascular Technology at Leipzig Interventional Course
REDWOOD CITY, Calif., Jan. 19, 2017 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of abstracts and sessions highlighting the company’s Lumivascular™ technology at the upcoming Leipzig Interventional Course (LINC) taking place next week in Leipzig, Germany, from Tuesday, January 24, through Friday, January 27, 2017....
Nov 03, 2016 04:01 pm ET
Avinger Announces Third Quarter 2016 Results
REDWOOD CITY, Calif., Nov. 03, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the third quarter ended September 30, 2016....
Oct 27, 2016 04:01 pm ET
Avinger to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif., Oct. 27, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the Company will be participating in two upcoming investor conferences....
Oct 25, 2016 04:01 pm ET
Avinger Launches Upgraded Lightbox Imaging Console
REDWOOD CITY, Calif., Oct. 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced the U.S. launch of an enhanced version of the company’s Lightbox imaging console. The Lightbox provides a dual display of images to physicians using Avinger’s Lumivascular system, the first-ever image-guided atherectomy and chronic total occlusion (CTO) recanalization devices for the treatment of peripheral artery disease (PAD), providing physicians with a view inside diseased arteries. The upgraded Lightbox L...
Oct 24, 2016 04:01 pm ET
Avinger to Announce Third Quarter 2016 Results on Thursday, November 3, 2016
REDWOOD CITY, Calif., Oct. 24, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the third quarter of 2016 after the close of trading on Thursday, November 3, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET....
Oct 20, 2016 04:01 pm ET
Avinger Announces Schedule of Sessions Highlighting Lumivascular Technology at TCT 2016
REDWOOD CITY, Calif., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced a schedule of abstracts and sessions highlighting the Company’s Lumivascular™ technology at the upcoming Transcatheter Cardiovascular Thereaputics (TCT) conference taking place in Washington, DC from October 29-November 2, 2016....
Oct 19, 2016 04:01 pm ET
Avinger Announces Expanded FDA Indications for Pantheris™ as Diagnostic Imaging Device
REDWOOD CITY, Calif., Oct. 19, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for Peripheral Artery Disease (PAD), today announced that the company has received expanded indications from the U.S. Food and Drug Administration (FDA) recognizing the Pantheris™ Lumivascular atherectomy system as a technology that can be used for both therapeutic and diagnostic purposes. ...
Sep 13, 2016 04:01 pm ET
Avinger Signs Agreement with U.S. Department of Veterans Affairs for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 13, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced the company has received an FSS Contract Award from the U.S. Department of Veterans Affairs (VA) which establishes terms under which VA hospitals across the country may acquire Avinger’s portfolio of Optical Coherence Tomography (OCT) image-guided catheters for their veterans hospitals....
Sep 07, 2016 04:01 pm ET
Avinger Signs Agreement with HealthTrust for Lumivascular Technology
REDWOOD CITY, Calif., Sept. 07, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a developer of innovative treatments for peripheral artery disease (PAD), today announced it has signed an agreement with HealthTrust. The agreement establishes terms under which members of the HealthTrust group purchasing organization may acquire Avinger’s portfolio of technologies designed to treat PAD, including Avinger’s PantherisTM Optical Coherence Tomography (OCT) image-guided atherectomy system, which recently received 510(k) clearance from the United States Food & Drug Administration (FDA). T...
Aug 16, 2016 04:01 pm ET
Avinger, Inc. Announces Closing of Public Offering of Common Stock and Underwriters’ Full Exercise of Option to Purchase Additional Shares
REDWOOD CITY, Calif., Aug. 16, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the closing of its previously announced public offering of 9,857,800 shares of Avinger’s common stock at a price to the public of $3.50 per share, which includes the exercise in full by the underwriters of their option to purchase an additional 1,285,800 shares of Avinger’s common stock. The total net proceeds from the offering are estimated to be approximately $31.7 million, after deducting ...
Aug 11, 2016 08:30 am ET
Avinger, Inc. Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced the pricing of its public offering of 8,572,000 shares of its common stock at a price to the public of $3.50 per share. In addition, the Company has granted the underwriters a 30-day option to purchase up to 1,285,800 additional shares of its common stock. The Company expects to close the offering on August 16, 2016, subject to customary closing conditions....
Aug 10, 2016 04:05 pm ET
Avinger, Inc. Announces Proposed Public Offering of Common Stock
REDWOOD CITY, Calif., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that it intends to offer, subject to market and other conditions, newly issued shares of common stock, $0.001 par value (the "Offering" with such shares being the "Shares") in an underwritten public offering under an effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”). The final terms of the Offering will depend on market and other conditions...
Aug 10, 2016 11:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Avinger, Inc. (AVGR)
NEW YORK, Aug. 10, 2016 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities Avinger, Inc. ("Avinger" or the "Company") (NASDAQ: AVGR). Such investors are advised to contact Peretz Bronstein or his investor relations analyst, Yael Hurwitz at info@bgandg.com or 212-697-6484....
Aug 09, 2016 07:30 am ET
Avinger, Inc. Announces Participation in Canaccord Genuity 36th Annual Growth Conference
REDWOOD CITY, Calif., Aug. 09, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that the Company plans to participate in the Canaccord Genuity 36th Annual Growth Conference in Boston....
Aug 01, 2016 04:01 pm ET
Avinger, Inc. Announces Second Quarter 2016 Results
REDWOOD CITY, Calif., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR) (the “Company”), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today reported results for the second quarter ended June 30, 2016....
Jul 25, 2016 04:01 pm ET
Avinger, Inc. to Announce Second Quarter 2016 Results on Monday, August 1, 2016
REDWOOD CITY, Calif., July 25, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the second quarter of 2016 after the close of trading on Monday, August 1, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET....
Jul 14, 2016 03:00 pm ET
INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Violations of Federal Securities Laws by Certain Officers and Directors of Avinger, Inc. - AVGR
NEW YORK, July 14, 2016 /PRNewswire/ -- Levi & Korsinsky announces it has commenced an investigation of Avinger, Inc. (NASDAQ: AVGR) ("Avinger") concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.  ...
Jul 13, 2016 12:29 pm ET
Avinger Shareholder Alert: Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of Avinger, Inc.; Investors Encouraged to Contact Firm
SAN DIEGO, July 13, 2016 /PRNewswire/ -- Shareholder Rights Law Firm Johnson & Weaver, LLP is investigating potential violations of the federal securities laws by Avinger, Inc. (NASDAQ: AVGR). Avinger is a commercial-stage medical device company that designs, manufactures and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD). ...
Jul 12, 2016 04:01 pm ET
Avinger, Inc. Announces Preliminary Second Quarter 2016 Revenue Results
REDWOOD CITY, Calif., July 12, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that based on preliminary unaudited financial results, it expects total revenue of approximately $4.7 million for the second quarter ended June 30, 2016, an increase of 57% from the second quarter of 2015.  ...
Jun 27, 2016 04:01 pm ET
Highmark Health’s VITAL Program to Evaluate Avinger’s Novel Treatment for Peripheral Artery Disease
PITTSBURGH and REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Highmark Health, Allegheny Health Network (AHN) and Avinger, Inc. (NASDAQ:AVGR) announced a collaboration today to evaluate Pantheris™, Avinger’s novel image-guided atherectomy device for the treatment of peripheral artery disease (PAD). The partnership is part of Highmark Health’s VITAL (Verification of Innovation by Testing, Analysis and Learning) Innovation Program....
Jun 15, 2016 04:01 pm ET
Avinger, Inc. Announces Drawdown of $10 Million Under Term Loan Facility with CRG
REDWOOD CITY, Calif., June 15, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc., (NASDAQ:AVGR) a leading developer of innovative treatments for peripheral artery disease (PAD), announced today that it has completed its second drawdown under the previously announced term loan facility with CRG LP (formerly known as Capital Royalty) and its affiliate funds ("CRG") for proceeds of $10 million before closing fees. The term loan facility gives the Company access to borrow up to $50 million, inclusive of the initial draw of $30 million in September 2015 and this tranche of $10 million. Upon achieving cert...
Apr 27, 2016 04:01 pm ET
Avinger, Inc. to Announce First Quarter 2016 Results on Wednesday, May 4, 2016
REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today announced that it will release its financial results for the first quarter of 2016 after the close of trading on Wednesday, May 4, 2016. The Company will host a corresponding conference call beginning at 1:30pm PT/4:30pm ET....

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please subscribe. Our packages start at $1.00 plus tax for the first month.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.